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A B S T R A C T
Therapeutic biomacromolecules are confronted with in vivo challenges of low bio-stability and poor tumor
tissue-penetration. Herein, we report for the first time, our development and characterization of a hybrid na-
nocomposite for delivering a Bcl-2-converting peptide (NuBCP9, N9 hereafter) and testing its efficacy alone or
together with doxorubicin (DOX). The hybrid nanocomposite is composed of the internal large pore sized-me-
soporous silica nanoparticles (MSNs) and the external highly-branched polyamidoamine (PAMAM) dendrimers,
into which N9 peptide and DOX were encapsulated for the different sub-cellular delivery to treat drug-resistant
cancer. The nanocomposite possessed the particle and pore sizes of ~37 nm and ~8 nm, which displayed the
superior tumor penetration capacity over naked MSNs both in cultured-3D tumor sphere and in live animal
models. Moreover, the dual drug nanocomposite exhibited a great synergistic anticancer effect on Bcl-2-positive
cancer cells in vitro and animals with the negligible toxic side effects. The tumor inhibition rate of the nano-
composite (89%) was five times as much as the two drugs combination. This design provides a new effective, safe
and versatile strategy to fabricate large pore-sized MSNs with the organic-inorganic hybrid framework to con-
currently transport therapeutic peptides and chemotherapeutics to the specific sub-cellular locations for the
synergistic cancer therapy and drug resistance reversal, which has significant impact on the development of
improved cancer therapeutics.
1. Introduction
B-cell leukemia/lymphoma-2 (Bcl-2) family proteins, both anti-
apoptotic and proapoptotic, have shown prognostic significance for
many types of cancer [1]. Bcl-2, a member of the anti-apoptotic factors
in the Bcl family, is often over-expressed in various human cancers,
including hematologic malignancies and various solid tumors [2,3].
The over-expression of Bcl-2 has been demonstrated to inhibit cell
death which is induced by various stimuli, such as hypoxia, oxidative
stress, and cytotoxic anticancer drugs. Moreover, the overexpression of
Bcl-2 is closely correlated with the resistance of tumor cells to radio-
and chemo-therapies [4]. Thus, Bcl-2 is a specific target for cancer
multidrug resistance (MDR) treatment.
Nur77, an orphan member of the steroid-thyroid hormone-retinoid
nuclear receptor superfamily, was reported to be closely associated with
responses to chemotherapeutics in patients with diffuse large B-cell
lymphoma [5]. We previously reported the apoptotic effect of Nur77
that involves its translocation from the nucleus to mitochondria where
it interacts with Bcl-2, resulting in a phenotypic of Bcl-2 from an anti-
apoptotic protein to a pro-apoptotic protein [6,7]. Moreover, we
identified a short peptide with 9 amino acids (NuBCP9, i.e., N9) from
Nur77, which is capable of binding and converting Bcl-2 [8]. N9 pep-
tide displays the excellent anticancer effects in Bcl-2-sensitive cancers
both in vitro and in animal models [8]. However, delivery of N9 into
cells usually requires its conjugation with the cell-penetrating DArg
octamer (r8), the non-selectivity and the serious toxicity of cell-pene-
trating peptide (CPPs) [9] largely limit the further development of N9.
Thus, the identification of safe peptide drug penetration carrier through
biological barriers is badly needed. Singh et al. employed the PLA-PEG-
PPG-PEG tertablock nanoparticle system to encapsulate N9 or the SPIO
nanoparticle conjugating N9 for the anticancer applications [10,11].
We also developed the large pore-sized silica nanoparticles with
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different surface functionalities for the specific delivery of N9 peptide
to drug-resistant cancer cells in vitro [12]. However, further improve-
ment of in vivo bio-stability and tumor tissue-penetration capabilities of
these nanopeptides are still badly needed.
Recent advances have identified multifunctional nanostructures that
can deliver two or more therapeutics together to achieve the super-
additive therapeutic effects. The small pore sized-mesoporous silica
nanoparticles (MSNs) by surface decoration with G2 amine-terminated
polyamidoamine (PAMAM) dendrimers or Poly(etherimide) (PEI) were
constructed to encapsulate doxorubicin (DOX) within the mesopores
and anchor Bcl-2/P-gp siRNA on the outer surface of MSNs to treat
multidrug-resistant cancer cells [13,14]. However, siRNA cross-linked
on the nanoparticle surface inevitably suffered from the premature gene
degradation by enzymes in the cellular microenvironment. Because of
the pore-size limitation of the conventional MSNs, it is highly desirable
to develop the new MSNs with large pore size to realize the efficient
encapsulation of the biomacromolecules. The large pore-sized hollow-
structured MSNs (HMSNs) were recently fabricated by employing the
diverse pore-expanding agents and surface decoration of poly (β-amino
esters) (PAE), which were used to simultaneously deliver the pore-
loaded P-gp siRNA and anticancer drug DOX for the reversal of the
MDR in breast cancer cells [15]. Herein, we for the first time, present a
different strategy to construct the large pore sized-MSNs (not HMSNs)
through the control of chemical conditions and surface decoration with
G5 PAMAM dendrimers to concurrently transport N9 peptide and DOX
into different sub-cellular compartments (mitochondrion and nucleus)
for the synergistic treatment against drug resistant cancers. Our
strategy was that the utilization of large pore-sized MSNs ~ PAMAM
nanocomposites instead of the small pore-sized ones will not only
protect therapeutic peptide within the macropore from activity deac-
tivation and uncontrolled release, but also improve the tumor-pene-
tration and retention capabilities of the peptide, resulting in an en-
hanced synergistic therapeutic outcome in Bcl-2-abundant cancers to
conquer the Bcl-2-associated MDR.
Based on the fabrication of N9 peptide and DOX-co-loaded
MSNs ~ PAMAM hybrid nanocomposites, in this present study, we se-
lected the Bcl-2-abundant or stable cervical and hepatocellular carci-
noma cell lines as the in vitro target models [8], and constructed the
Bcl-2-overxpressed HepG2 tumor xenograft mice as the in vivo tracking
model [16,17] for the evaluation of tumor-targeting and penetrating
capability and the final antitumor efficiency of the above dual drug
nanocomposites. These assays are expected to demonstrate the en-
hanced tumor penetration ability of peptide and the killing of cancer
cells by dual nanodrugs in a synergistic manner.
2. Experimental section
2.1. Materials
The main synthesis materials for MSNs including triethanolamine
(TEA, ≥98%), hexadecyl trimethyl ammonium chloride (CTAC,
≥98%), tetraethyl orthosilicate (TEOS, 98%), 3-aminopropyltriethox-
ysilane (APTES, ≥98%), and succinic anhydride (SA, ≥99%) were
closely described in our previous studies [12,18]. PAMAM dendrimers
(generation 5, 128 amine end groups), Rhodamine 123 (i.e., Rho 123),
DAPI, CY7 and [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrasodium
bromide] tetrazolium salt (MTT) were obtained from Sigma-Aldrich.
Bcl-2-converting peptide (FSRSLHSLL, N9, ≥98%) was synthesized and
purified by LifeTein (Beijing) Ltd. Fluorescence-labeled peptides in-
cluding N9-Rhodamine B (i.e., N9-RB) and N9-FITC (i.e., N9-FI) were
synthesized by GL Biochem (Shanghai) Ltd. Doxorubicin hydrochloride
(DOX·HCl) was purchased from Meilun bio Co., Ltd. Antibodies against
Bcl-2 and Bcl-2 BH3, and horseradish peroxidase-labeled secondary
antibodies were provided by Cell Signaling Technology (CST). Mito-
Tracker (Deep Red) was purchased from Life Company. Annexin V-FITC
Apoptosis Detection Kit and SYTOX were purchased from BD Bioscience
(San Diego, CA, USA). Caspase 3 Kit was purchased from Beyotime
Biotech Inc. TUNEL Apoptosis Detection Kit (Alexa Fluor 647) was
purchased from Yeasen Biotech Co., Ltd. Immunohistochemistry-related
reagents were purchased from Zhongshan jing qiao Biotechnology co.,
Ltd. Deionized water was used in all experiments. All other chemicals,
unless otherwise specified, were all purchased from Sinopharm Che-
mical Reagent Co., Ltd and used without further purification.
2.2. Preparation of N9@M~G5~DOX nanocomposites
The large pore-sized MSNs were synthesized and loaded with Bcl-2
converting peptide (N9) after surface functionalized with carboxylic
group following the procedures previously described [12,18]. Briefly,
CTAC (2g) and TEA (0.18g) were dissolved in ddH2O (80 ml) at 95 °C
for 1h, followed by addition with TEOS (1.5 ml) slowly for 2h, then
MSNs were collected after washing with ethanol and 1% NaCl methanol
solutions for serval times. MSNs were successively functionalized with
amino groups and carboxyl groups by reacting with APTES in ethanol at
90 °C overnight, and then with SA at room temperature for 12h. N9
peptides were finally loaded into the pores of the carboxyl groups-de-
corated MSNs (i.e., M-C) at 800 rpm, 4 °C for 24h in ddH2O. To wrap
the G5 PAMAM dendrimers (i.e., G5) on the surface of N9@M-C na-
noparticles, N9@M-C and G5 were mixed according to the mass ratio of
1:10, and stirred gently at 4 °C overnight. The G5-modified N9@M-C
nanoparticles (i.e., N9@M ~ G5) were collected by centrifugation at
14000 rpm for 30min after removal of the excess G5 by ddH2O washing.
Dual drug-co-loaded nanocomposites (i.e., N9(@M ~ G5~DOX) were
then formulated by mixed N9@M ~ G5 (10 mg/ml) and DOX (2 mg/
ml) at the ratio of 1:1 (v/v) for 24h of stirring. The N9-FI, N9-RB or CY7
loaded nanoparticles were similarly synthesized as above except the
replacement of N9 solution with N9-FI, N9-RB or CY7 solution. The
loading efficiency (LE) and encapsulation efficiency (EE) of N9-RB and
DOX were determined based on the UV absorption values at 316 nm
and 484 nm, respectively, and calculated by the following formulas: LE
% = (initial amount of drug - residual drug)/(the total amount of na-
noparticles) *100%, EE%= (initial amount of drug - residual drug)/
initial amount of drug * 100%.
2.3. Characterization of N9@M~G5~DOX nanocomposites
To determine the physiochemical properties of the final N9@
M ~ G5~DOX nanoparticles, dynamic light scattering (DLS), field
scanning electron microscope (FSEM), transmission electron micro-
scope (TEM) and laser scanning confocal microscope (LSCM) mea-
surements were taken. The hydrophilic diameter and zeta potential of
nanoparticles at each step were measured by a DLS analyzer (Malvern
Nano ZS90) with the mass concentration of 0.1 mg/ml in pure water.
The particle shape, size, pore structure, and surface with G5 coating of
M-C nanoparticles were characterized both by FSEM and TEM images,
which were respectively performed on a SEM equipment (Zeiss, SUPRA
55) at 20 kV after uniformly dispersed on silica substrate and com-
pletely dried overnight in drying cabinet, or on a TEM (Tecnai G2 Spirit
BioTwin) operating at 200 kV after filtered by copper screen, dried and
stained with 0.2% phosphotungstic acid. The fluorescence images of
N9-FITC@M ~ G5 and N9-FITC@M ~ G5~DOX nanocomposites were
also obtained under LSCM to verify whether N9-FITC and DOX were
loaded into the nanocomposites.
2.4. In vitro N9 peptide and DOX release studies
The in vitro N9-FI and DOX release from N9-FI@M ~ G5~DOX
nanocomposites was evaluated by placing 3.6 mg of N9-FI@M ~ G5
NPs or 1 mg of M ~ G5~DOX dialyzed in PBS with different pH values
at 7.4, 6.8 and 5.0. Periodic sampling was then carried out at
300 rpm at 37 °C ± 1 °C for different time intervals (2, 4, 6, 12, 24, 48,
96h) to determine the fluorescence intensity of the released N9-FI or
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DOX. At the same time, the same volumes of PBS solutions (0.4 ml) with
different pH values were replenished to the corresponding N9-FI@
M ~ G5 or M ~ G5~DOX suspension to keep the total volume of the
mixture constant. The original or released drug content was respec-
tively calculated based on the standard curve of free N9-FI or DOX, and
the corresponding curve of cumulative release percentage versus time
was plotted.
2.5. Cell culture and Bcl-2 expression analysis
The parental and Bcl-2- transfected human cervical carcinoma cell
lines (HeLa and HeLa-Bcl2) were cultured in minimum essential
medium (MEM), the parental and Bcl-2- transfected human hepatocel-
lular carcinoma cell lines (HepG2 and HepG2-Bcl2 with GFP labeling)
were cultured in dulbecco's modified eagle's medium (DMEM), and the
human non-small-cell lung cancer cells (H292) and DOX-resistant
human breast cancer cells (MCF-7/DOX) were cultured in RPMI-1640
culture medium. All the above media were supplemented with 10% of
fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS). Human
pulmonary microvascular endothelial cells (HPMEC) were purchased
from the iXCells Biotechnologies (San Diego, CA, USA), and cultured in
endothelium cell medium (ECM) supplemented with 5% FBS, 100 μg/
ml ECGS, 100 units/ml penicillin and 100 μg/ml streptomycin. All the
cell lines were maintained at 37 °C in a humidified atmosphere of 5%
CO2, after reached the confluence of 80–90%, harvested using 0.25%
trypsin and re-suspended in fresh medium for subsequent experiments.
Specially stated, HeLa-Bcl2 and HepG2-Bcl2-GFP cell lines, respec-
tively constructed by our and Dr. Wu's labs as previously reported
[16,17,19], were used to confirm the therapeutic effects of N9@M ~ G5
and N9@M ~ G5~DOX nanocomposites against resistant cancers. Thus,
their up-regulated expression levels of Bcl-2 were verified before use by
western blotting and fluorescence imaging methods. The expression
levels of Bcl-2 in other cells were also examined using the same method.
2.6. Anti-proliferation effect of N9@M~G5~DOX nanocomposites
To test the cytotoxicity of N9@M ~ G5~DOX, MTT assay was
performed on various wild type cancer cell lines (HeLa, HepG2, H292)
and resistant cancer cell lines (HeLa-Bcl2, HepG2-Bcl2, MCF-7/DOX).
All the cell lines above were seeded in 96-well plates at a density of
3000 cells/well and grown for 24h. Then cells were individually in-
cubated with various drug formulations (N9, DOX, DOX + N9, N9@
M ~ G5, N9@M ~ G5~DOX) in complete media at gradient DOX
concentrations (0.1, 0.5, 1, 2, 5, 10 μg/ml) or the equivalent N9 con-
centrations (0.5, 2.5, 5, 10, 25, 50 μg/ml). Cells without any treatment
were used as the negative controls. After 48h, the media containing
particles and drugs were removed, 100 μl of fresh medium containing
MTT (200 μg/ml) was added to each well for another 4h. The super-
natant was then aspirated and replaced with 100 μl of DMSO per well to
dissolve the water-insoluble blue formazan. The optical absorption
value was finally read at the wavelength of 490 nm on a microplate
reader (Promega Glomax® Discover). The inhibitory effects of various
drug formulations on each above cell lines were expressed as the per-
centage of A490 nm of the treated group compared to that of the un-
treated group.
2.7. Intracellular localization of N9 and DOX in cervical cancer cells
Fluorescence images were taken using N9-FI instead of N9 to clearly
observe the intracellular delivery behaviors of N9@M ~ G5~DOX in
HeLa-Bcl2 and HeLa cells, HeLa-Bcl2 and HeLa cells were seeded into
24-well plates with glass coverslips coated on the bottom at a density of
1000 cells/well and cultured in a humidified atmosphere of 5% CO2 at
37 °C overnight. After attachment, cells were treated with N9-FI, N9-
FI@M-C, N9-FI@M ~ G5 at N9-FI concentration of 5 μg/ml for 2h and
24h, or with N9-FI@M ~ G5~DOX at DOX concentration of 0.5 μg/ml
for different incubation intervals (2, 5, 10, 24h). At the given time
points, cells were washed and stained with mitotracker-deep red
(75 nM) for 30min in serum-free medium at 37 °C. After labeling, cells
were washed and fixed with 1% paraformaldehyde overnight at 4 °C,
followed by incubation with DAPI solution (1 μg/ml) for another
10 min at room temperature. After several times of washing with PBS,
the coverslips were taken out and mounted on glass slide for images
taken under a LSCM.
2.8. Quantification of cellular uptake efficiency
The cellular uptake efficiencies of N9 and DOX by HeLa-Bcl2 and
HeLa cells were quantitatively measured by flow cytometry. HeLa-Bcl2
and HeLa cells were seeded into 6-well plate at a density of
1 × 105 cells/well and grown overnight. When reached the confluence
of 70%, cells were respectively exposed to the media containing N9-FI,
DOX, N9-FI + DOX, N9-FI@M ~ G5~DOX at DOX concentrations of
1 μg/ml and/or the equivalent N9-FI concentration of 5 μg/ml for
different time intervals (2, 10, 24 h). The cells without any treatment
were used as control. All the cells were detached by 0.25% trypsin
solution and washed twice with PBS. Finally, the collected cells were
subjected to flow cytometric analysis (Beckman Coulter cytoflex), and
the uptake efficiency of N9 and DOX by cancer cells was respectively
determined by the intracellular PE (DOX) and FITC (N9) fluorescence
intensity, which displayed with the shift of curve in the treated cells
compared to control.
Whether N9-FI@M ~ G5~DOX nanocomposites could penetrate the
biological barrier not just cancer cells, their penetration behaviors in
endothelial HPMEC cells were similarly investigated by LSCM and flow
cytometric analyses after incubation of N9-FI@M ~ G5~DOX with
HPMEC for 12h. The same dose of free N9-FITC or DOX was also tested
as the positive controls.
2.9. Penetration in HepG2-Bcl2-GFP-cultured multicellular spheroids
Penetration abilities of the synthesized nanocomposites were eval-
uated using the artificial multicellular tumor spheroids in vitro as
previously reported [20–23]. HepG2-Bcl2-GFP tumor spheroids were
cultured by seeding HepG2-Bcl2-GFP cells onto 1% agarose (W/V)
-coated 96-well plates at a density of 600 cells/100 μl per well. After 7
days, the tumor spheroids reaching the uniform size of 400 μm were
incubated with media containing N9-RB@M-C or N9-RB@M ~ G5 at
the same N9-RB concentration of 10 μg/ml for 10h. Then tumor
spheroids were rinsed with PBS, fixed by 1% paraformaldehyde over-
night at 4 °C in dark, and finally imaged by LSCM from top to down at
various Z axis heights.
2.10. Cell apoptosis analysis
The relative percentage of apoptotic cells was assessed with SYTOX
and Annexin V-FITC staining by flow cytometry. HepG2, HeLa and
HeLa-Bcl2 cells were seeded in 6-well plates at a density of
1 × 105 cells/well and grown overnight. Cells were then incubated
with various drug formulations (N9, DOX, DOX + N9, N9@M ~ G5,
N9@M ~ G5~DOX) at DOX concentration of 1 μg/ml and the equal N9
concentration of 5 μg/ml for 48h, and cells without any treatment were
used as negative control. After cells were trypsinized and washed for
three times with ice-cold PBS, the re-suspended cells were then in-
cubated with 100 μl of binding buffer containing 5 μl Annexin V-FITC
for 15min prior to the addition of 5 μl SYTOX solutions (5 μM) for
10min. Finally, the apoptosis-inducing effects among these drug for-
mulations were detected on a flow cytometer. Taken the above proce-
dure, the induction of apoptosis in HepG2 cells was also qualitatively
observed by LSCM by virtue of the Annexin V-FITC and/or SYTOX-
stained cell images.
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2.11. Cellular MMP measurement
Change in mitochondrial membrane potential (MMP) usually in-
dicates the cell apoptosis in early stage. The cellular MMP was eval-
uated by flow cytometry based on the fluorescence intensity of Rho 123
(a lipotropic cationic fluorescent dye) from cells. HeLa-Bcl2 and HeLa
cancer cells were cultured in 6-well plates at a density of 1 × 105 cells/
well and grown overnight. After attachment, cells were incubated with
various drug formulations (N9, DOX, DOX + N9, N9@M ~ G5, N9@
M ~ G5~DOX) at DOX concentration of 1 μg/ml and/or the equal N9
concentration of 5 μg/ml for 24h, cells without any treatment were
used as control. After collected by 0.25% trypsin solution, cells were
stained with Rho 123 working solution (3 μg/ml) in complete medium
at 37 °C for 30min. Finally, flow cytometry was used to quantitatively
measure the percentage of Rho 123- positive cells between the treated
groups and the control ones.
2.12. Analysis of Bcl-2 conformational change by Bcl2-BH3 exposure
The exposure of the Bcl2 BH3 domain in cancer cells was considered
as an important indicator of N9 converting from an anti-apoptotic
molecule to a pro-apoptotic molecule [8]. Thus, the exposed amount of
Bcl2-BH3 induced by N9@M ~ G5 nanocomposites was evaluated.
HeLa-Bcl2 and HeLa cancer cells were seeded in 6-well plates at a
density of 1 × 105 cells/well and grown overnight. Then cells were
incubated with naked N9 or N9@M ~ G5 at N9 concentration of 5 μg/
ml for 24h and 48h, respectively. At the given time point, cells were
collected after trypsinized and washed with PBS, fixed with 1% paraf-
ormaldehyde overnight at 4 °C. After permeabilized with 0.05% Triton
X-100 solution on ice, Bcl2-BH3 antibody was added into the cell sus-
pensions and incubated for 3h, followed by the addition of FITC-labeled
secondary antibody for another 2h at room temperature. The exposed
amount of Bcl2-BH3 was finally detected on a flow cytometer and
shown by the intracellular FITC intensity in the treated groups com-
pared to that in the negative control group.
2.13. Cell cycle arrest analysis
To evaluate the effects of DOX-loaded nanoparticles on the dis-
tribution of cell population in every phase (G0/G1, S and G2/M), cell
cycle was analyzed with DAPI staining. Briefly, HepG2-Bcl2, HeLa-Bcl2
and HeLa cells were seeded on 6-well plates at a density of
1 × 105 cells/well. After treatment with the various drug formulations
(N9, DOX, DOX + N9, N9@M ~ G5, N9@M ~ G5~DOX) at DOX
concentration of 1 μg/ml or the equal N9 concentration for 24 h, cells
were treated with trypsin and washed with ice cold PBS for three times.
Then cells were collected and fixed with 70% ice-cold ethanol overnight
at 4 °C. Fixed cells were washed with ice-cold PBS and stained with
DAPI solution (1 μg/ml) at room temperature for 10 min. Data acqui-
sition and analysis were finally obtained on a flow cytometer (Beckman
Coulter cytoflex) and analyzed with CytoExpert software, respectively.
2.14. Caspase 3 activity analysis
To determine the apoptosis-inducing efficiency of N9@
M ~ G5~DOX nanocomposites on HepG2-Bcl2-GFP cells, the caspase-3
activity was detected by ELISA analysis. HepG2-Bcl2-GFP cells were
seeded into 6-well plates at a density of 1 × 105 cells/well for attach-
ment overnight. Cells were then exposed to the fresh medium con-
taining various drug formulations (N9, DOX, DOX + N9, N9@M ~ G5,
N9@M ~ G5~DOX) at DOX concentration of 1 μg/ml or equal N9
dosage for 48 h, cells without any treatment were used as control. After
washed, trypsinized, and collected, cells were then treated with cas-
pase-3 activity detection kit as the instructor indicated, and finally
measured at the wavelength of 405 nm on a microplate reader. The
caspase-3 activity of cells induced by various drug formulations were
expressed as the percentage of A405 nm of the treated group compared to
that of the untreated group.
2.15. Animals and xenograft model establishment
Female BALB/c nude mice were kept under an individual ventilated
cage (IVC) system and fed with distilled food and water in Department
of Experimental Animals, Xiamen University (Xiamen, China). All an-
imal experiments were approved by the institutional Animal Ethics
Committee in accordance with the Animal Care Guidelines of Xiamen
University.
To set up the tumor xenograft model, HepG2-Bcl2-GFP cancer cells
were detached, calculated and suspended in PBS at the concentration of
2 × 106 cells/200 μl, female nude mice (6 week old) were sub-
cutaneously inoculated with 200 μl cell suspension at the right flank or
on the right leg. The HepG2-Bcl2 tumor-bearing nude mice were suc-
cessfully built by taking the published methods [16,17,24]. The tumor
size was monitored by a Vernier caliper and the tumor volume (V) was
calculated as V = LW2/2, where L and W were the length and width of
the tumor, respectively. When the tumor volume reached around
100–200 mm3, various treatments were initiated.
2.16. In vivo imaging and bio-distribution studies
NIR probes-loaded nanoparticles were synthesized prior to the
evaluation of systemic targeting of nanocarriers in vivo. Briefly, 200 μL
of CY7@M-C and CY7@M ~ G5 nanoparticles at the same particle dose
of 30 mg/kg were intravenously administered to the HepG2-Bcl2-GFP
tumors-bearing nude mice via the tail vein. At different time intervals
after post-injection (0.5h, 1h, 3h, 7h, 12h, 24h), the mice were an-
esthetized and imaged under an in vivo PerkinElmer IVIS optical ima-
ging system. At the designated time points (12, 24h), mice were eu-
thanized, the tumor and the major organs (such as heart, liver, spleen,
lung, kidney and intestine) were excised for ex vivo imaging to show
the bio-distribution of the above two nanoparticles.
2.17. Pharmacokinetics study
SD rats (~200 g) were chosen to study the pharmacokinetics of
CY7@M ~ G5 and free CY7. Rats were randomly divided into two
groups (n = 3) and individually injected with CY7@M ~ G5 nano-
particle and free CY7 at CY7 dose of 1.0 mg/kg through tail vein. Blood
samples were obtained from caudal vein of SD rats at different time
points (30 min, 1 h, 3 h, 6 h, 9 h, and 24 h), and centrifuged at 5000 rpm
for 10 min at 4 °C for collection of the plasma. The aliquots of plasma
were stored at −80 °C until analysis of CY7 concentration by fluores-
cence spectrophotometry. Pharmacokinetic profile of CY7@M ~ G5
nanoparticle and CY7 were finally analyzed by pharmacokinetic soft-
ware Drug and Statistics Software (DAS) version 2.0. For toxicity as-
sessment, SD rats were intravenously administrated with M ~ G5 na-
noparticles (30 mg/kg). At 24h of post-injection, the blood was
collected for the complete blood count (CBC) analysis on an automatic
blood cell analyzer (Mindray, BC-2800vet). The effects of M ~ G5 na-
noparticles on blood cells were also evaluated.
2.18. In vivo anti-tumor studies
The in vivo tumor growth inhibition efficiency of various drug
formulations was further studied. The established HepG2-Bcl2-GFP
tumor-bearing mice were weighed and sorted into different groups (5
mice/group) randomly when the tumor volume reached to 80 mm3,
followed by tail vein injection of various drug formulations (N9, DOX,
DOX + N9, M ~ G5, N9@M ~ G5, N9@M ~ G5~DOX) at 0.5 mg/kg
DOX or equal N9 dosage of 1.75 mg/kg or equal M ~ G5 nanocarrier of
28.5 mg/kg once every two days for two weeks. Both the body weight
and tumor size of mice were monitored throughout the whole
J. Xie, et al. Cancer Letters 469 (2020) 340–354
343
treatments. At the end 15th day, all the mice were euthanized, and the
excised tumors in each group were photographed and weighed. The
collected tumors and other major organs were then fixed in 4% paraf-
ormaldehyde to prepare the tissue paraffin-embedded sections for the
following biochemical analysis. For the hematoxylin and eosin (H&E)
and Ki-67 staining, the slides of tumors and other organs were observed
by an optical microscope under bright field. For the TUNEL apoptosis
assay, the tumor sections were stained with the TUNEL Alexa-647 Kit
according to the manufacturer's protocol and observed by LSCM.
2.19. Statistical analysis
Data were shown as the mean ± standard deviations of n ≥ 3, and
statistical analysis was performed by GraphPad Prism 5.0 software
using Student's t-test and one-way analysis of variance (The differences
were considered statistically significant, very significant, and extremely
significant for p value < 0.05, p < 0.01 and p < 0.001, respec-
tively).
3. Results and discussion
3.1. Design and synthesis of Bcl-2-converting peptide and DOX-co-
encapsulated hybrid nanoparticles
The large pore sized-MSNs with carboxyl groups were prepared as
we previously reported [12,18], followed by surface modification with
G5 amine-terminated PAMAM dendrimers via electrostatic interaction.
The Bcl2-converting peptide (N9) and DOX were successively en-
capsulated into the macropore of MSNs and the three-dimensional
cavity of PAMAM as shown by the schematic diagram (Fig. 1A). The
coating of PAMAM dendrimers on surface of MSNs was not only ben-
eficial for protecting peptide from degradation and inactivation, but
also for improving the tumor cell-penetration capability to achieve the
site-specific drug release. The fact that PAMAM enables the deep and
uniform tumor penetration to reach more drugs on cancer cells has been
demonstrated many times [13,22]. The zeta potential measurements
(Fig. 1B, b) showed that surface charge was converted from
−26 ± 0.7 mV to +35.3 ± 1.01 mV after carboxyl-decorated MSNs
was modified with PAMAM dendrimers, indicating the successful pre-
paration of the hybrid nanoparticles. In the process of dual drug-loading
system, the hydrodynamic diameter of nanoparticles was still kept less
than 200 nm and PDI value was around 0.1 (Fig. 1B, a), which will
largely contribute to its facile circulation in blood and effective EPR
effect in tumor tissues. Our TEM and SEM measurements (Fig. 1C, a)
further confirmed that the hybrid nanoparticles possessed the macro-
porous inner structure and the spherical surface morphology. The
successful modification of MSNs outer space with G5 PAMAM den-
drimers was also demonstrated both by the enlarged particle size from
31.4 ± 1.88 nm to 36.9 ± 1.66 nm calculated from SEM images
(Fig. 1C, b) and the significant increments in percentages of C (from
0.65% to 2.85%) and N (from 2.72% to 6.77%) elements obtained from
SEM-EDS analysis (Fig. 1C, c) after G5 coating. With the sequential
encapsulation, the unique fluorescence colors of FITC-labeled N9
(green) and/or DOX (red) from the hybrid nanoparticles imaged under
a fluorescence inverted microscope further demonstrated the successful
loading of single or dual drugs (Fig.1D, a-b), and the loading efficiency
of N9 and DOX in each M ~ G5 nanocomposite was (10.89 ± 0.97) %
and (2.15 ± 0.48) %, respectively. It seemed that N9-FITC and DOX
could be respectively released from the macropore and hybranched
cavity of M ~ G5 nanocomposites (Fig.1E, a-b). There was a burst re-
lease before 12h, followed by a slow release over 96h. The cumulative
release rate of N9-FI at pH7.4 was 33% and that of DOX at pH5.0 was
24% until 96h. The DOX release behavior was in an obvious pH-sen-
sitive manner (Fig. 1E, b), where the cumulative release at pH5.0
seemed to be higher than that at pH7.4. In contrast, the lack of acid-
responsive release characteristics of N9-FI peptide (Fig. 1E, a) was as
same as what previously reported [10,25], which might be related to its
isoelectric point (PI = 9.76). Moreover, the slower release at pH5.0
than that at pH7.4 might be favorable for the less release of N9 peptide
in lysosome, thereby causing less degradation and improved bio-stabi-
lity.
3.2. Inhibition of proliferation on various cancer cell lines
The anti-proliferation capabilities of dual drug-loaded hybrid na-
noparticles on various cell lines including Bcl-2-expressing or over-ex-
pressed cancer cells were primarily evaluated. MTT results (Fig. 2A-C)
showed that free N9 peptide without nanocarriers hardly caused cyto-
toxicity to any cell line, which was consistent with previous reports [8].
In contrast, with the delivery of hybrid nanoparticles (M ~ G5), the cell
viability was concentration-dependently decreased by N9 in varying
degrees in different cell lines. In comparison with single drug coun-
terparts (N9, DOX, and N9@M ~ G5) or combined two drugs
(DOX + N9), the designed dual drugs-loaded hybrid nanoparticles
(N9@M ~ G5~DOX) exhibited the significantly synergistic anti-pro-
liferation capacities. However, the varying inhibition capacity of dual
nanodrugs was embodied in different cell lines. It seemed that the vi-
abilities of sensitive cells such as HeLa, HepG2 and H292 were almost
totally restrained by N9@M ~ G5~DOX nanodrugs at a low DOX
concentration of 0.5 μg/ml after 48h of co-incubation (Fig. 2A-C, a). In
contrast, the viabilities of Bcl-2-overexpressed transgenic HeLa and
HepG2 cells, and DOX-resistant MCF7 cells were not significantly de-
creased by the dual nanodrugs, which might be largely attributed to the
MDR produced by the abundance of Bcl-2 or P-gp protein [12,18].
However, the dual nanodrugs could still induce the death of more than
90% HeLa-Bcl2 cells at the low DOX concentration of 0.5 μg/ml, and
more than 80% HepG2-Bcl2 and MCF7/DOX cell death at the relatively
higher DOX concentration of 10 μg/ml (Fig. 2A-C, b). The discrepancy
in cell viability inhibition might be due to the different levels of Bcl-2
protein in the above cell lines (Fig. S1). IC50 values in Table S1 further
indicated that Bcl-2-overexpressed cancer cells were resistant to free
DOX relative to other sensitive cells, and the chemotherapeutic-re-
sistance was increased in the order of HeLa-Bcl2, HepG2-Bcl2, and
MCF7/DOX with corresponding IC50 values of 0.472, 1.873, and
6.012 μg/ml. After delivering DOX and N9 into cancer cells with the
hybrid nanoparticles, the resistance was largely reversed, and the cell
viability was sharply decreased more than fourteen, six, and three times
compared to the two drugs in combination. Moreover, the IC50 values
of dual nanodrugs were less than 0.1 μg/ml against these sensitive
cancer cell lines, suggesting their prominent anticancer efficiency.
Thus, these results collectively confirmed that our designed dual na-
nodrugs not only exerted their anticancer capabilities in sensitive
cancer cells, but in chemotherapeutic-resistant cancer cells.
3.3. LSCM analysis of internalization behaviors of peptide or/and DOX-co-
encapsulated nanoparticles
The clinical application of peptide/protein drugs in cancer treat-
ment is well-known to be largely hampered by their instability and poor
cell penetrative capabilities in vivo [8,10]. Without the assistance of
cell-penetrating peptide or nanocarriers, anticancer peptide N9 was
hardly delivered to the designated intracellular position to efficiently
induce tumor cell into apoptotic status. Our previous studies had de-
monstrated that N9 peptide could be specifically delivered onto mi-
tochondria by MSNs with large pore size for treating cancer MDR in
vitro [12]. To investigate whether N9 peptide and DOX could be, re-
spectively, delivered to mitochondria and nucleus by our designed
hybrid nanoparticles either in Bcl2-expressing or Bcl2-overexpressed
cancer cell lines, blue and deep red fluorescence labeling was per-
formed to distinguish the nucleus from cytoplasm. Firstly, we evaluate
the cell-penetration capabilities between M-C and M ~ G5 nano-
particles in delivering the targeting peptide. LSCM images (Fig. 3A, Fig.
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S2A) showed that free N9 peptide couldn't enter into cells within 24h
from the absence of green fluorescence while it could be taken into
cytoplasm, especially mitochondria, both by M-C and M ~ G5 nano-
particles. Moreover, the cellular internalization and mitochondria lo-
calization degree was enhanced with the incubation time prolonged
from 2h to 24h as observed by the merged white fluorescence colors.
The increased region of white colors both in HeLa-Bcl2 and HeLa cells
demonstrated the stronger cell-penetrative capability of M ~ G5 nano-
particles relative to that of M-C, which was in consistent with the
previous studies that cationic particles showed the increased uptake
than zwitterionic and anionic particles with the increasing particle size
[26]. On the basis of the above results, we then further investigated the
co-delivery efficiency of DOX and N9 peptide in HeLa-Bcl2 and HeLa
cells by the above hybrid nanoparticles (M ~ G5). The presence of red
Fig. 1. Design and characterization of DOX
and N9 peptide-co-loaded nanocomposites
for the synergistic anticancer evaluation. A,
The synthesis routine about the above dual
drug co-delivery system based on large pore
sized-silica nanoparticles (MSNs) and G5
PAMAM dendrimers. Note, M-N, M-C, N9,
MSNs ~ G5 are the abbreviations of MSNs-
NH2, MSNs-COOH, NuBCP-9 and
MSNs ~ G5 PAMAM dendrimers, respec-
tively. B, Hydrodynamic diameter (a) and
zeta potential (b) measurements of a series
of nanoproducts at each step in ddH2O at
0.1 mg/ml. C, SEM and TEM images (a) of
M-C nanoparticles before and after surface
modification with G5 PAMAM dendrimers,
and the corresponding particle size dis-
tribution (b) and element composition (c)
analyses. TEM images were obtained by
nanoparticles filtered by copper screen,
dried and stained with (outer) or without
(inner) 0.2% phosphotungstic acid. The
inner TEM images showing the typical
dendrimer-like structure and large pore size
properties. Particle diameter and element
content results were obtained from large
numbers of nanoparticles in the obtained
SEM images. D, The fluorescence images of
single or dual drug-loaded nanocomposites
at different excitation wavelengths. a, N9-FI
peptide-loaded nanocomposites; b, DOX
and N9-FI-coloaded nanocomposites. E, The
in vitro release profiles of N9-FI (a) and
DOX (b), respectively, from N9-FI@
M ~ G5~DOX nanocomposites in PBS at
different pH values.
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fluorescence in nucleus and green fluorescence in perinuclear region of
cytoplasm suggested the successful release of DOX and N9 peptide,
respectively, from the external cavity structure and internal macropore
of M ~ G5 nanoparticles. Moreover, the specific cellular localization
behaviors of DOX and N9 peptide were shown in a time-dependent
manner, confirming the successful fabrication of the co-delivery system
(Fig. 3B, Fig. S2B). All of these results will pave the way for the final
anticancer efficiency of the co-delivery system in a synergistic manner.
3.4. Quantitative analysis of cell uptake behaviors of peptide and DOX
mediated by hybrid nanoparticles
To quantitatively analyze the uptake efficiency of N9 peptide and
DOX by HeLa or HeLa-Bcl2 cancer cells, flow cytometry procedures
were performed after their co-incubation with free DOX, N9 peptide or
DOX and N9-encaspualted nanocomposites for different incubation
times at the DOX concentration of 1 μg/ml. The cell uptake efficiency of
DOX and N9 was respectively determined based on the average
fluorescence intensity of intracellular DOX and FITC. It seemed that free
DOX could enter into HeLa-Bcl2 or HeLa cancer cells in a time-depen-
dent way and the cellular uptake efficiency reached over 80% at 2h and
nearly 100% at 10h (Fig. 3C, Fig. S3, upper). In contrast, there was
almost no increment on FITC fluorescence intensity with time pro-
longed from 2h to 24h, indicating that free N9 peptide couldn't pene-
trate into cells without the assistance of the carriers (Fig. 3C, Fig. S3).
With the delivery of M ~ G5 nanocomposites, DOX or N9 peptide could
be delivered into cancer cells, and the intracellular DOX and N9 amount
reached 100% even at 2h (Fig. 3C, Fig. S3). Thus, the cellular uptake
behaviors of dual drugs were obviously improved by our designed na-
nocomposites, which will benefit for their synergistic anticancer func-
tions in vitro and in vivo.
Besides, the penetration behaviors of N9-FITC@M ~ G5~DOX na-
nocomposites in endothelial cells that imitate biological barriers were
also evaluated by LSCM and flow cytometric methods. It was observed
that N9-FITC (green color) and DOX (red color) could be respectively
delivered into the cytoplasm and nucleus of HPMEC cells by M ~ G5
Fig. 2. In vitro cytotoxic effects of various drug formulations on different wild type (A-C, a) and drug resistant (A-C, b) cancer cell lines after 48h of exposure. The
inhibitory effects on cell growth induced by dual drug nanocomposites were compared with that by single drug counterparts and combined two drugs. A, The symbols
a-b represent HeLa and Bcl2 overexpressed-HeLa (HeLa-Bcl2); B, a-b, HepG2 and HepG2-Bcl2; C, a-b, H292 and DOX reisistant-MCF7 (MCF7/DOX).
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nanoparticles after 12h of co-incubation (Fig. 3D, a). Quantitative
analysis also demonstrated N9-FITC and DOX with the delivery of
M ~ G5 nanoparticles could be taken into HPMEC cells, and the cellular
uptake efficiency of N9-FITC and DOX, respectively, reached over 80%
and 90% compared to the control and free N9-FITC-treated cells
(Fig. 3D, b). In a word, these results collectively provided the evidence
that N9-FITC@M ~ G5~DOX nanocomposites could not only penetrate
into cancer cells but endothelial cells.
3.5. The key roles of N9 peptide in cancer cell apoptosis delivered by hybrid
nanoparticles
A series of flow cytometry assays were carried out to validate the
important roles of N9 peptide and DOX in the final anticancer activities
of nanosystem. Our previous research has demonstrated that N9 pep-
tide, a Bcl-2-targeting therapeutic, is able to induce changes in mi-
tochondrial function [8]. Thus, we firstly verified whether the cancer
Fig. 3. Qualitative and quantitative analyses of the cell penetration and intracellular internalization behaviors of N9-FI and DOX in Bcl2-stable cervical cancer cells
(HeLa-Bcl2) and human pulmonary microvascular endothelial cells (HPMEC) delivered by the hybrid nanocomposites, respectively, under a LSCM and on a flow
cytometer. A, The cell-penetrating capabilities among free N9, N9@M-C, and N9@M ~ G5 at 2h (a) and 24h (b) in HeLa-Bcl2 cancer cells at the same N9 con-
centration of 5 μg/ml. B, The co-localization capabilities of N9 and DOX with mitochondria and nucleus in HeLa-Bcl2 cells delivered by M ~ G5 hybird nanoparticles
for different time intervals with the DOX concentration of 0.5 μg/ml. Especially stated, green and red fluorescence colors, respectively, indicated the presence of N9
peptide and DOX in cells. C, Flow cytometry analyses of the cellular uptake efficiencies of free DOX, N9, and N9@M ~ G5~DOX in HeLa-Bcl2 cells in response to
various incubation time intervals at the DOX concentration of 1 μg/ml. The DOX and N9 uptake efficiency by cancer cells was respectively determined by the
intracellular DOX and FITC fluorescence intensity, and displayed with the shift of curve in the treated cells compared to control without any treatment. D, LSCM (a)
and flow cytometric (b) analyses of the penetration abilities of N9-FITC@M ~ G5~DOX at DOX concentration of 0.5 μg/ml in human endothelial HPMEC cells that
mimic biological barriers after co-incubation for 12h. Scale bar: 25 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the
Web version of this article.)
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cellular MMP would be largely changed by N9 peptide after the delivery
with M ~ G5 nanocomposites. Usually, the increment in fluorescence
intensity of Rho 123 means the decline in cellular MMP. It was found
that naked DOX and/or N9 hardly caused any influence on MMP in wild
type HeLa cells or Bcl-2-overexpressed HeLa cells (Fig. 4A, Fig. S4),
which might be mainly attributed to the non-target on mitochondria of
DOX and the weak cell-penetration capacity of free N9. However, with
the assistance of M ~ G5 nanocarriers, both dual drug nanosystem and
Fig. 4. Flow cytometric analyses of the effects of DOX and N9 in various drug formulations on HeLa-Bcl2 cancer cells. A, Change in intracellular mitochondria
membrane potential specifically caused by N9 with various drug formulations. B, Investigation of the time-dependent exposure of Bcl2-BH3 domain after N9
delivered into cells by the M ~ G5 nanocomposites, and bound with Bcl-2 on mitochondria. C, Cell cycle arrest in HeLa-Bcl2 cells induced by the intracellular DOX.
All the cells were collected after incubation with various drug formulations at the same DOX concentration of 1 μg/ml or equal N9 concentration of 5 μg/ml for 24h.
D, The apoptosis effects of HeLa-Bcl2 cells induced by various drug formulations (N9, DOX, N9+DOX, N9@M ~ G5, N9@M ~ G5~DOX) at the same DOX
concentration of 1 μg/ml or equal N9 concentration of 5 μg/ml for 48h. E, DAPI staining showing the cell cycle distribution and cell apoptosis analyses in GFP-labeled
Bcl2-overexpressed hepatocellular cells (HepG2-Bcl2) induced by N9 and/or DOX-loaded nanocomposites at DOX concentration of 1 μg/ml for 24h. F, ELSIA analysis
of the caspase 3 activity in HepG2-Bcl2 cells after incubated with equivalent DOX concentration of 1 μg/ml for 48h.
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single N9 counterparts produced the decreased MMP compared to
controls in HeLa and HeLa-Bcl2 cell lines. Especially, the MMP was
decreased by 50% in HeLa-Bcl2 cells (Fig. 4A) by the dual nanodrugs,
and by 30% in HeLa cells (Fig. S4), suggesting the significance of
M ~ G5 nanocomposites in the cellular function of N9 peptide in a Bcl2-
dependent manner.
Furthermore, it is a prerequisite for the apoptosis-inducing function
of N9 peptide that binds to Bcl-2 on mitochondria and makes a con-
formational change to expose the BH3 domain [8]. Thus, the exposure
of BH3 domain is another factor for the final anticancer activity of N9
peptide. Flow cytometry analysis (Fig. 4B, Fig. S5) showed that a strong
enhancement in fluorescence was detectable upon staining with BH3
antibody of cells exposed to N9@M ~ G5 nanodrugs but not naked N9
peptide. Moreover, the BH3 domain exposure was in a time-dependent
way, especially at 48h, N9@M ~ G5 nanodrugs induced approximately
37% (Fig. S5) and 24% (Fig. 4B) amount of BH3 domain exposure,
respectively, in HeLa and HeLa-Bcl2 cell lines. These results further
confirmed that N9 peptide-induced Bcl2-dependent apoptosis was clo-
sely correlated with exposure of Bcl-2 BH3 domain by virtue of M ~ G5
nanocarriers.
The synergistic anticancer activities of dual drug nanocomposites
will be up to the dual functions of DOX and N9 peptide in cells. Thus,
the effects of DOX alone and DOX-loaded nanoparticles on cell cycle
distribution were investigated. Relative to control, N9 peptide as a Bcl-2
target almost caused no influence on cell cycle distribution both in
HeLa and HeLa-Bcl2 cell lines (Fig. 4C, Fig. S6). In contrast, free DOX,
the combined DOX and N9 peptide, and the DOX and N9-loaded na-
nocomposites arrested the cell cycle both in S and G2/M phases in
varying degrees. Due to the increased amount of DOX in nucleus of
cancer cells delivered by M ~ G5 nanocomposites, the anti-proliferation
ability of dual drug nanocomposites was sharply improved compared to
the free DOX and the two drugs combination, which induced approxi-
mately 35% cell population in S phase and 26% in G2/M phase relative
to the normal controls (Fig. 4C). The mild apoptosis phenomenon was
also observed in the treated cells with N9@M ~ G5~DOX nano-
composites. Therefore, it could be inferred that specific delivery of DOX
and N9 peptide to the designated position of cancer cells might de-
termine their final anticancer effects acting synergistically.
3.6. Synergistic apoptosis functions of peptide and DOX mediated by hybrid
nanoparticles
To assess the apoptosis effects of dual drug nanocomposites on
human cervical cancer cell lines (HeLa and HeLa-Bcl2), Annexin V-
FITC/STOXY-blue staining method was performed on the treated HeLa
and HeLa cells with various drug formulations. Above all, the optimal
incubation conditions for the induction of apoptosis were firstly de-
termined based on drug action concentrations. As depicted from the
quantitative flow cytometry analysis (Fig. S7, a-b), there was an en-
hanced apoptosis effect in response to the increased concentration of
DOX from 0.5 to 2 μg/ml after 24h of exposure. Moreover, treatment of
N9@M ~ G5~DOX resulted in greater apoptosis rate (45%) than DOX/
N9 alone or combination (18%) or N9@M ~ G5 counterparts (22%)
especially in HeLa-Bcl2 cells (Fig. S7b). However, HeLa cells were so
sensitive to free DOX that more than 80% of apoptosis rate was ob-
tained at 2 μg/ml, and the enhanced synergistic effect of N9@
M ~ G5~DOX nanodrugs was observed at DOX concentration of 0.5 μg/
ml, leading to 80% of cell population into apoptotic status in compar-
ison of DOX/N9 combined (40%) or N9@M ~ G5 counterparts (22%)
(Fig. S7a). Thus, we continued to evaluate the apoptosis-inducing
ability of N9@M ~ G5~DOX nanocomposites at DOX concentration of
1 μg/ml for the longer incubation time of 48h. Flow cytometric images
(Fig. 4D, Fig. S7, c-d, and Fig. S8) showed that cell populations were
divided into four quadrants of scatter plot, in which cell percentage at
the early and late apoptotic status was obviously increased by various
drug formulations compared to control and naked N9 peptide.
Interestingly, M ~ G5 nanoparticles could take N9 peptide into cancer
cells, and further contribute to the improved apoptosis rates of 25% and
16%, respectively, in HeLa and HeLa-Bcl2 cells, demonstrating their
effective delivery efficiency. Importantly, dual drug nanocomposites
N9@M ~ G5~DOX exhibited the significantly effective capability in
inducing HeLa-Bcl2 cancer cells into apoptosis (Fig. 4D) with a much
higher percentage of apoptotic cells (79%) observed relative to DOX/
N9 (52%) and N9@M ~ G5 (17%), indicating that co-delivery of DOX
and N9 by M ~ G5 nanocomposites produced cancer cell apoptosis in a
synergistic manner.
3.7. Synergistic enhancement of apoptosis in hepatocellular cancer HepG2
cells
To further examine whether the combination effects of dual drug
nanocomposites would be similarly present in liver cancers, a series of
assays were carried out after co-incubation of HepG2 or HepG2-Bcl2-
GFP cells with various drug formulations for a defined time period.
After the treated HepG2 cells were stained with Annexin V-FITC/
SYTOX dyes, flow cytometry and LSCM analyses were both made to
quantitatively and qualitatively show the apoptosis effects of dual drug
nanocomposites. The results (Figs. S9 and A) displayed that HepG2 cells
were sensitive to DOX, but not to free N9, with 40% apoptotic cells.
Interestingly, the apoptosis-inducing effect of naked DOX was slightly
higher than that of dual drug nanocomposites (30%), which might be
attributed to the slow drug release from M ~ G5 nanocomposites in
these cells. Confocal images (Figs. S9 and B) also demonstrated that
treatment with DOX, N9@M ~ G5, and N9@M ~ G5~DOX was asso-
ciated with the induction of apoptotic response, which could be vi-
sualized from the green (early apoptosis) and blue (late apoptosis)
fluorescence colors of cells. By contrast, treatment with naked N9
peptide had no effect, which was almost as same as the control cells.
The enhanced apoptotic response in cells treated with N9@
M ~ G5~DOX nanodrugs in comparison with single drug alone or the
combination of two drugs again confirmed the effectiveness of M ~ G5
nanocomposites as the intracellular delivery vehicles.
After 24h of exposure to different drug formulations, cell cycle
analysis in Bcl2-overexpressed HepG2 cells again demonstrated the
inhibition of cell cycle at S phase by free DOX and DOX-loaded nano-
drugs, and the induction of cell apoptosis by N9-loaded single and dual
nanodrugs (Fig. 4E). The dual drug nanocomposites still displayed the
enhanced apoptosis-inducing effect of about 13% more than N9@
M ~ G5 nanoparticles. Moreover, caspase 3 activity as an apoptosis
indicator was further measured after HepG2-Bcl2 cells were treated
with the above drug formulations for 48h. The enhancement of caspase-
3 activity usually indicates the depth of cell apoptosis. It seemed that
naked N9 peptide nearly caused no change in caspase 3 activity. By
contrast, N9@M ~ G5~DOX nanocomposites treatment resulted in the
increased caspase 3 activity in comparison with DOX, DOX and N9
combination, and N9@M ~ G5 treatments in a synergistic way
(Fig. 4F). These data collectively demonstrated that the synergistic
anticancer functions of N9@M ~ G5~DOX nanocomposites would be
applied not only in cervical cancer cells but also liver cancer cells, and
possibly other cancer cells with elevated levels of Bcl-2.
3.8. In vitro artificial tumor sphere penetration
Multicellular spheroids (MCSs) have been proposed as an in vitro
3D-cultured tumor model to evaluate the tumor penetration and
therapy efficiency of nanotherapeutics [22]. In this study, we also es-
tablished the GFP-labeled HepG2-Bcl2 human liver MCSs (green color)
to compare the tumor penetration capability of M-C nanoparticles and
M ~ G5 nanocomposites in delivering RB-labeled N9 peptide (red
color). LSCM analysis (Fig. 5A) showed that N9 peptide was attached to
the periphery of MCSs after 2h of incubation, and the red fluorescence
intensity was then gradually increased in MCSs over time both in M-C
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and M ~ G5-treated groups. After 10h, the red fluorescence signals
were also detected in the internal area of MCSs (Fig. 5B), demonstrating
the strong tumor-penetration characteristics of small sized-MSNs na-
noparticles [23]. By contrast, a more noticeable red fluorescence signal
in the internal area of MCSs in the Z-stack images was detected from
M ~ G5 nanocomposites than M-C nanoparticles (Fig. 5, A-B), revealing
the improved tumor-penetration capacity of MSNs nanoparticles after
their surface coating with amine-decorated PAMAM dendrimers, con-
sistent with previous reports [13,22]. The superior tumor sphere-pe-
netration capability of M ~ G5 nanocomposites over M-C was also
embodied in the overlapping of red-green color areas and the pene-
tration depth of N9 peptide in the interior region of MCSs in the pro-
vided 3D dynamic video and the merged 3D images (Fig. 5C), which
was consistent with the above-mentioned stronger cell-penetration and
cellular accumulation capabilities of PAMAM coating for N9 delivery in
vitro (Fig. 3). Quantitative analysis of Fig. 5B further showed that the
mean fluorescence intensity inside the N9-RB@M ~ G5-positive MCSs
maintained stronger than that in N9-RB@M-C-positive MCSs even with
the scanning depth from −20μm to −120μm (Fig. S11), indicating G5
PAMAM decorated on M-C nanoparticle surface enabled the penetra-
tion enhancement of N9 peptide in vivo.
3.9. In vivo tumor targeting and accumulation
The specific targeting and enhanced accumulation efficacy of
M ~ G5 nanocomposites in tumor was further validated by in vivo real-
time imaging. The M-C and M ~ G5 nanoparticles were encapsulated
with CY7 dye for the near-infrared fluorescence imaging to trace their
target position in HepG2-Bcl2-GFP tumor-bearing nude mice [27] after
their intravenous administration by tail vein at the same dosage of
30 mg/kg for different time-points (0.5, 1, 3, 7, 12, 24h). As shown in
Fig. 6A, the fluorescence signals in tumor sites were clearly observed
both in the CY7@M-C and CY7@M ~ G5-treated groups after 3h of post
injection, demonstrating their effective tumor-specific delivery as na-
nocarriers. As time elapsed, the fluorescence intensity in tumor was
gradually decreased, while that in the normal sites, especially liver, was
relatively increased in the CY7@M-C-treated mice (Fig. 6A, upper).
This might be due to dissociation of some CY7 from the nanoparticles
[28]. By contrast, a noticeable fluorescence signal of CY7@M ~ G5 was
still observed in tumor site at 24h after treatment even though the
fluorescence intensity was obviously decreased throughout the body
(Fig. 6A, down), whereas the fluorescence intensity in M-C-treated
mice was sharply decreased and hardly detected, suggesting the superb
Fig. 5. A, Comparison of the HepG2-Bcl2 tumor-penetration capabilities between N9-RB@M-C (left) and N9-RB@M ~ G5 (right) nanoparticles in artificial 3D
tumorsphere models in vitro with exposure time prolonged from 2h to 24h. DAPI and Rhodamine B labeling were used to show the presence of tumor cells and N9
peptide. B, LSCM Z-stack scanning images of HepG2-Bcl2 multi-cellular spheres (MCSs) after treated with N9-RB@M-C and N9-RB@M ~ G5 for 10h. C, The ste-
reoscopic images of GFP-labeled MCSs after treated with N9-RB@M-C and N9-RB@M ~ G5 nanoparticles for 10h showing their difference in penetration abilities.
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tumor accumulation capability of M ~ G5 nanoparticles over M-C na-
noparticles. The detail bio-distribution of two nanoparticles was also
investigated respectively at 12 and 24h of post-injection time points
after mice were autopsied. The ex vivo fluorescence imaging of the
major organs (Fig. 6B) displayed that both M-C and M ~ G5 nano-
particles could reach tumor site at 12 and 24h of post-injection, but part
of them were also localized at normal organs. Quantitative analysis
further displayed that the relative percentage of fluorescence intensity
from tumor was enhanced, and that from liver was decreased with time
prolonged from 12h to 24h (Fig. 6C). Strikingly, it was also found that
although CY7@nanoparticles was distributed in the tissues of liver,
spleen and kidney, only M ~ G5 but not M-C nanoparticles were partly
localized in the lung. The reason for the different bio-distribution of the
two nanoparticles might be attributed to the surface charge character-
istic of MSNs nanoparticles [29]. Besides, the ex vivo tumor accumu-
lation intensity of M-C seemed to be higher than that of M ~ G5 (Fig.6C,
a-b), which was somewhat different from the above phenomenon
(Fig. 6, A-B). The possible reason might be explained by the different
CY7 loading efficiency at the same dosage of nanoparticles and the
different bio-distribution of nanoparticles in the selected but not total
organs. Anyhow, this assay again confirmed that drugs encapsulated
into the pores of MSNs could be successfully delivered into tumor
tissue.
To further determine the pharmacokinetic profiles of free CY7 and
CY7@M ~ G5 nanodrug, the fluorescence spectra was used to quanti-
tatively analyze the level of CY7 in the mouse plasma in response to
different time points after intravenous administration. It was found that
(Fig. 6D, a) the plasma level of CY7 in the CY7@M ~ G5-treated mice
was rapidly increased, peaked at 4h not 2h, and gradually decreased
over 24h. The maximum plasma concentration of CY7 in the CY7@
M ~ G5 group was also higher than that in the free CY7 group. After
calculation by pharmacokinetic software, the values of T1/2, AUC0-t,
MRT0-t, Tmax and Cmax for CY7@M ~ G5 were bigger than that for free
CY7, especially AUC0-t and MRT0-t. CY7@M ~ G5 nanodrug showed
Fig. 6. A, In vivo real-time NIR imaging of
nude mice bearing HepG2-Bcl2 tumors after
post tail-vein injection of CY7@M-C or
CY7@M ~ G5 at the same particle dose of
30 mg/kg to show the tumor targeting and
accumulation capacities. B-C, The bio-dis-
tribution of the above two nanoformula-
tions (a, CY7@M-C; b, CY7@M ~ G5) in
mice tumor and other tissues (heart, liver,
spleen, lung, kidney, intestine) at 12h and
24h time points reflected both by the ex
vivo fluorescence images (B) and the
average fluorescence signal (C) of CY7. D,
The plasma levels of CY7 over the period of
24h in female mice (n = 3) after in-
travenous injection of free CY7 or CY7@
M ~ G5 at CY7 dose of 1 mg/kg (a). Blood
was collected at the designated time points
for the analysis of CY7 concentration using
fluorescence spectrophotometry. The phar-
macokinetic parameters of free CY7 and
CY7@M ~ G5 were analyzed by pharmaco-
kinetic software Drug and Statistics
Software (DAS) version 2.0 (b). The data
were expressed as means ± SD, and statis-
tical analysis was also shown.
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higher Cmax of 8.97 ± 2.54 μg/ml at Tmax of 3h compared with free
CY7, and the blood half time of CY7@M ~ G5 was prolonged to
2.12 ± 0.26 h (Fig. 6D, b). These data indicated that the pharmaco-
kinetic characteristics of free drug (e.g., CY7) were significantly im-
proved after M ~ G5 nanoparticle delivery. Meanwhile, the toxicity of
M ~ G5 nanocarrier on blood and blood cells was also evaluated after
24h of post-injection by complete blood count analysis. The various
indexes in Table S2 showed that M ~ G5 nanocomposites produced the
slight inflammatory reaction but no effects on red blood cells (RBCs)
compared to saline group, suggesting the relatively great blood com-
patibility.
Collectively, our in vitro and in vivo results demonstrated the re-
markable tumor targeting, accumulation and penetration capabilities of
M-C nanoparticles after G5 PAMAM dendrimers coating with no he-
mocompatibility, which will largely contribute to the delivery efficacy
of therapeutics at the tumor site and the final therapeutic effects.
3.10. In vivo antitumor therapy evaluation in HepG2 subcutaneous tumor-
bearing mice
Given the effective accumulation and penetration of M ~ G5 nano-
composites in tumors, we next evaluated the superior performance of
dual drug-loaded nanocomposites over single drug counterparts in an-
titumor efficiency in vivo. BALB/c mice bearing established sub-
cutaneous HepG2-Bcl2-GFP hepatocellular carcinoma tumors were in-
travenously administrated with saline, N9, DOX, N9 and DOX, M ~ G5
nanocarrier, N9@M ~ G5, and N9@M ~ G5~DOX at DOX dosage of
0.5 mg/kg via tail vein followed by measurements of the tumor volumes
and body weight at every two days (Fig. 7A). A fast tumor growth of the
saline, N9 or M ~ G5-treated groups was observed within 15 days,
Fig. 7. Evaluation of the anti-tumor efficacy of DOX and N9-co-loaded nanocomposites in human hepatocellular carcinoma xenograft models. A, Schematic diagram
of the treatment process by HepG2-Bcl2-GFP tumor-bearing mice intravenously administrated with various drug formulations at 0.5 mg/kg DOX or equivalent N9
dosage once every two day intervals for two weeks. B, Representative photographs of mice with subcutaneous tumors in different sizes after various treatments at the
end study day. C, Tumor volume growth curves of mice in various drug treatment groups compared to the saline control. D, Change in tumor weight by various
treatments at the end of experiment. E, Measurements of body weight during the study to evaluate the systemic toxicity of various drug formulation treatments. F,
Images of the excised tumors from mice with the continuous treatments for 15 days.
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indicating the non-effect of free N9 peptide and nanocarriers on tumors
in vivo. Besides, the naked DOX and DOX/N9 combination-treated mice
showed little tumor growth inhibition compared to that of saline-
treated group (Fig. 7B), implying the poor therapeutic efficiency of
naked drug in vivo due to a series of biological barriers that it en-
countered [30]. In contrast, with the delivery of M ~ G5 nanocarriers,
N9@M ~ G5 and N9@M ~ G5~DOX-treated groups displayed the sig-
nificantly excellent tumor growth inhibition capabilities than naked
drug or drug combination-treated groups. This was reflected in the
sharply decreased tumor volumes (Fig. 7C). The above therapeutic ef-
fects were also intuitively embodied in the mice photos and the excised
tumor images at the end of treatment day (Fig. 7B, F). Apart from the
reduction of tumor size, the average tumor weight was also sharply
decreased in the N9@M ~ G5 and N9@M ~ G5~DOX -treated mice
groups in comparison with other groups (Fig. 7D). The inhibition rates
were 89%, 84%, 17% for N9@M ~ G5~DOX, N9@M ~ G5, N9/DOX
treatments relative to the saline controls. Notably, N9@M ~ G5~DOX
treatment almost completely inhibited the growth of the HepG2-Bcl2-
GFP tumor (Fig. 7, A, D, F), demonstrating an excellent efficacy of the
dual drug nanocomposites in tumor suppression. Strikingly, during the
treatment period, no obvious change was found in the body weight,
food and water intake amounts of mice among different drug for-
mulations-treated groups (Fig. 7E, Fig. S10), revealing the biosafety of
nanocarriers at the highly bearable dosage of ~30 mg/kg and the
negligible toxic side effects of nanodrugs. It is worth mentioning that
the maximum tolerated dose of fluorescent MSNs (FMSNs) via in-
travenous administration into female nude mice once per day for 10d
has been demonstrated to be below of 100 mg/kg, because the mice
treated with FMSNs more than 100 mg/kg showed the mild elevation of
liver transaminase aspartate aminotransferase [31]. Thus, the dose of
the hybrid nanoparticles (MSNs ~ PAMAM) at ~30 mg/kg might be
safe in vivo. Moreover, the presence of ethenylene groups on the surface
of MSNs showed lower hemolytic activity against RBCs than traditional
colloidal MSNs [32] and the toxicity was alleviated by surface mod-
ification of MSNs with primary amine groups [33], which provide an
alternative route to improve the hemocompatibility of MSNs by mole-
cularly integrated organic-inorganic hybridization. Thus, the
MSNs ~ PAMAM hybrid nanocarriers showed the great biocompat-
ibility and biosafety in blood when used through intravenous injection.
Histological analyses, including H&E, Ki67, and TUNEL staining,
were also performed to validate the superior antitumor efficacy of dual
drug nanocomposites over others. N9@M ~ G5~DOX again showed
excellent activities in inducing morphological changes and apoptosis,
and inhibiting proliferation of HepG2-Bcl2-GFP tumor cells as com-
pared to other treatments (Fig. 8A). Meanwhile, the potential damage
of dual drug nanocomposites to major organs of the tumor-bearing mice
was also evaluated. As shown in Fig. 8B, no obvious toxic side effects,
especially liver injury and nephritis, were present in the treated groups
with various drug formulations. The evaluated organs were almost the
same as that in the saline group, suggesting again their excellent in vivo
biosafety and biocompatibility of nanodrugs. Overall, M ~ G5 nano-
composites-based dual drug delivery system exhibited the prominent
therapeutic effects and the great biosafety in a xenograft liver cancer
model, which was consistent with the above in vitro results.
Fig. 8. Biochemical analyses of the effects of various drug formulations on mice organs during the study. A, H&E, TUNEL, and Ki-67 analyses of tumor tissues of mice
after the above treatments. B, Evaluation of the toxic side effects of various drug formulations on the major organs of mice (heart, liver, spleen, lung and kidney) by H
&E staining. Scale bar: 100 µm.
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4. Conclusions
In summary, we have successfully constructed a multi-organelle-
targeting sequential drug delivery system using macroporous silica
nanoparticles coated with highly-branched PAMAM dendrimers for
effective delivering N9 peptide and DOX to realize the combination
therapy on Bcl-2-abundant and resistant cancer. N9 peptide and DOX
could be successfully loaded into the macropores of MSNs and the in-
ternal cavity of PAMAM, which protected N9 peptide from the activity
deactivation and the uncontrolled release while improving the tumor-
penetration and retention capabilities. The DOX and N9-loaded nano-
composites exhibited the superior performance on therapy efficiency
against Bcl-2-overxpressed tumor over single drug counterparts or two
drugs combination with the negligible toxic side effects both in Bcl-2-
expressed or over-expressed cancer cell lines (HeLa and HepG2) and in
HepG2-Bcl2-bearing nude mice models. Overall, this work not only
provides a versatile nanosystem for the precise intracellular delivery of
peptide drugs and chemotherapeutics for the effective combination in
cancer therapy, but also opens doors for the potential application of Bcl-
2-converting peptide against tumor resistance.
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